Genetic factors, including germinal predispositions (e.g., the CCAAT/enhancer binding protein α—CEBPA and DEAD-Box Helicase 41—DDX41), Li Fraumeni syndrome (TP53), and bone marrow failure syndromes, are associated with both the onset and response to therapy for this condition [3]. This evidence concerns the gene DDX41 and bone marrow failure syndrome.